226 related articles for article (PubMed ID: 26802027)
1. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
[TBL] [Abstract][Full Text] [Related]
2. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.
Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D
Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191
[TBL] [Abstract][Full Text] [Related]
4. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
6. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M
Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083
[TBL] [Abstract][Full Text] [Related]
8. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
10. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
11. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
[TBL] [Abstract][Full Text] [Related]
12. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse.
Perotti D; Spreafico F; Torri F; Gamba B; D'Adamo P; Pizzamiglio S; Terenziani M; Catania S; Collini P; Nantron M; Pession A; Bianchi M; Indolfi P; D'Angelo P; Fossati-Bellani F; Verderio P; Macciardi F; Radice P;
Genes Chromosomes Cancer; 2012 Jul; 51(7):644-53. PubMed ID: 22407497
[TBL] [Abstract][Full Text] [Related]
14. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
15. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
16. High-resolution molecular cytogenetic analysis of Wilms tumors highlights diagnostic difficulties among small round cell kidney tumors.
Stewénius Y; Jin Y; Ora I; Panagopoulos I; Möller E; Mertens F; Sandstedt B; Alumets J; Akerman M; Merks JH; de Kraker J; Gisselsson D
Genes Chromosomes Cancer; 2008 Oct; 47(10):845-52. PubMed ID: 18615675
[TBL] [Abstract][Full Text] [Related]
17. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
[TBL] [Abstract][Full Text] [Related]
18. Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome.
Haruta M; Arai Y; Okita H; Tanaka Y; Takimoto T; Sugino RP; Yamada Y; Kamijo T; Oue T; Fukuzawa M; Koshinaga T; Kaneko Y
Neoplasia; 2019 Jan; 21(1):117-131. PubMed ID: 30530054
[TBL] [Abstract][Full Text] [Related]
19. Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.
Mengelbier LH; Karlsson J; Lindgren D; Øra I; Isaksson M; Frigyesi I; Frigyesi A; Bras J; Sandstedt B; Gisselsson D
Am J Pathol; 2010 Nov; 177(5):2609-21. PubMed ID: 20847289
[TBL] [Abstract][Full Text] [Related]
20. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.
Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y
Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
